Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 143, Issue 2, Pages 201-209Publisher
WILEY
DOI: 10.1111/j.1365-2141.2008.07271.x
Keywords
Ixabepilone; epothilones; indolent non-Hodgkin lymphoma; mantle cell lymphoma
Categories
Funding
- Leukemia and Lymphoma Society
- NCI Phase II [UO1 CA 69913]
- Vermont Cancer Center [P30CA22435]
Ask authors/readers for more resources
The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m(2) weekly for three of four consecutive weeks. Patients were required to have received <= 4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count > 1 x 10(9)/l and a platelet count > 50 x 10(9)/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available